235 related articles for article (PubMed ID: 36797666)
1. Serological response to vaccination in post-acute sequelae of COVID.
Joung S; Weber B; Wu M; Liu Y; Tang AB; Driver M; Sternbach S; Wynter T; Hoang A; Barajas D; Kao YH; Khuu B; Bravo M; Masoom H; Tran T; Sun N; Botting PG; Claggett BL; Prostko JC; Frias EC; Stewart JL; Robertson J; Kwan AC; Torossian M; Pedraza I; Sterling C; Goldzweig C; Oft J; Zabner R; Fert-Bober J; Ebinger JE; Sobhani K; Cheng S; Le CN
BMC Infect Dis; 2023 Feb; 23(1):97. PubMed ID: 36797666
[TBL] [Abstract][Full Text] [Related]
2. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
Wynberg E; Han AX; Boyd A; van Willigen HDG; Verveen A; Lebbink R; van der Straten K; Kootstra N; van Gils MJ; Russell C; Leenstra T; de Jong MD; de Bree GJ; Prins M;
Vaccine; 2022 Jul; 40(32):4424-4431. PubMed ID: 35725782
[TBL] [Abstract][Full Text] [Related]
3. PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females.
Jansen EB; Ostadgavahi AT; Hewins B; Buchanan R; Thivierge BM; Sganzerla Martinez G; Goncin U; Francis ME; Swan CL; Scruten E; Bell J; Darbellay J; Facciuolo A; Falzarano D; Gerdts V; Fenton ME; Hedlin P; Kelvin DJ; Kelvin AA
Sci Rep; 2024 Apr; 14(1):9854. PubMed ID: 38684819
[TBL] [Abstract][Full Text] [Related]
4. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.
Søgaard OS; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Stærke NB; Iversen K; Fogh K; Bodilsen J; Iversen M; Knudsen LS; Klastrup V; Larsen FD; Andersen SD; Hvidt AK; Andreasen SR; Madsen LW; Lindvig SO; Øvrehus A; Ostrowski SR; Abildgaard C; Matthews C; Jensen TO; Raben D; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Lundgren J;
Clin Microbiol Infect; 2022 Aug; 28(8):1126-1133. PubMed ID: 35283313
[TBL] [Abstract][Full Text] [Related]
5. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
6. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
[TBL] [Abstract][Full Text] [Related]
9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
12. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
13. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
14. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.
Herman JD; Atyeo C; Zur Y; Cook CE; Patel NJ; Vanni KM; Kowalski EN; Qian G; Srivatsan S; Shadick NA; Rao DA; Kellman B; Mann CJ; Lauffenburger D; Wallace ZS; Sparks JA; Alter G
Sci Transl Med; 2023 Sep; 15(712):eadf6598. PubMed ID: 37672567
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.
Tannous J; Pan AP; Potter T; Bako AT; Dlouhy K; Drews A; Sostman HD; Vahidy FS
BMJ Open; 2023 Apr; 13(4):e067611. PubMed ID: 37019490
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
20. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
